Skip to contentN
Nika Pharmaceuticals, Inc
N
NIKANika Pharmaceuticals, Inc Q1 2025 · 10-Q
Revenue—
Net Income-$12.95K-$12.95KN/M vs Q1 2024 EPS Diluted$0.00$0.00— vs Q1 2024 Operating Income-$12,945N/M Operating Cash Flow-$12,945N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nika Pharmaceuticals, Inc · CIK 1145604 · Engraved from SEC EDGAR
ended Mar 31, 2025 · filed May 13, 2025 · 43 d after period end